Biomab EGFR - Nimotuzumab 50mg INjection

Biomab EGFR - Nimotuzumab 50mg INjection Specification

Salt Composition
Nimotuzumab 50mg

Indication
Treatment of head and neck cancer, Glioma, and other EGFR-expressing cancers

Dosage Form
Injection

Enzyme Types
Monoclonal antibody (not a traditional enzyme)

Feature
Humanized monoclonal antibody; high specificity for EGFR; reduced risk of skin and allergic reactions

Ingredients
Each vial contains Nimotuzumab 50mg, sterile water for injection

Application
Anticancer therapy, targeted therapy for EGFR-positive tumors

Physical Color/Texture
Clear, colorless to slightly yellow solution

Fermentation Smell
Odorless

Enzymatic Activity
Not applicable (no enzymatic activity, monoclonal antibody action)

Storage Instructions
Store in a refrigerator at 2C to 8C. Do not freeze. Protect from light.

Shelf Life
18 months

Prescription Required
Yes

Reconstitution
Requires dilution as per manufacturer's instructions prior to administration

Strength
50 mg per vial

Packaging
Single-use vial

Route of Administration
Intravenous Infusion

Compatibility
Do not mix with other medicinal products except those mentioned in official guidelines

Caution
To be used under the supervision of a qualified physician experienced in cancer chemotherapy

Intended Patient Group
Adults (paediatric use as per oncologist's recommendation)

ATC Code
L01XC

Administration Frequency
As prescribed, typically once per week or as advised by the treating oncologist

About Biomab EGFR - Nimotuzumab 50mg INjection

Biomab EGFR - Nimotuzumab 50mg INjection:-

BIOMAb EGFR, a humanized monoclonal antibody falls under a class of cancer treatment option known as targeted therapy.
Targeted cancer therapies interfere with cancer cell growth and division in different ways and at various points during the development, growth, and spread of cancer. They target molecules specific to cancer cells and prevent the cancerous cells from growing, dividing and spreading uncontrollably.

BIOMAb EGFR (Nimotuzumab) is also known by the brand names Theracim, Theraloc, etc., in different countries where it is approved.

BIOMAb EGFR is currently approved for treatment of head and neck cancers in India, Cuba, Argentina, Colombia, Ivory Coast, Gabon, Ukraine, Peru, Vietnam and Sri Lanka; for glioma (pediatric and adult) in Cuba, Argentina, the Philippines, Myanmar, Mexico, Indonesia, Switzerland, Vietnam, Brazil and Ukraine; for nasopharyngeal cancer (a type of head and neck cancer) in China. It has been granted orphan drug status for Glioma in the USA and for Glioma and pancreatic cancer in Europe. A number of clinical trials are being conducted worldwide to evaluate the efficacy of this molecule in various other indications also like lung cancer, pancreatic cancer, cervical cancer etc

Precision Therapy for EGFR-Positive Tumors

Biomab EGFR - Nimotuzumab targets and blocks the activity of Epidermal Growth Factor Receptors found on certain cancer cells, helping inhibit their growth. With high specificity and lower risk of adverse skin and immune reactions, it represents a significant advancement in the management of EGFR-expressing cancers. Its use must be guided by a skilled oncologist, optimizing safety and effectiveness.

Recommended Administration and Handling

This medication is intended for intravenous infusion only, after appropriate dilution according to the manufacturers instructions. Biomab EGFR should never be mixed with other drugs unless specified in the guidelines. It is designed for use in adults; pediatric usage should be based on advice from an oncology specialist. Dosage and frequency will be tailored to the patients medical needs by the treating physician.

Storage and Stability

To maintain product quality, Biomab EGFR must be stored in a refrigerator at temperatures between 2C and 8C. The vials must not be frozen and should be kept away from light. Under recommended conditions, Biomab EGFR maintains its stability and efficacy for up to 18 months.

FAQs of Biomab EGFR - Nimotuzumab 50mg INjection:

Q: How is Biomab EGFR - Nimotuzumab 50mg Injection administered?

A: Biomab EGFR is administered intravenously as an infusion after it has been diluted with a suitable solution, following the instructions provided by the manufacturer. The procedure should always be carried out by healthcare professionals experienced in cancer therapy.

Q: What are the main indications for using Biomab EGFR?

A: Biomab EGFR is indicated for the treatment of head and neck cancers, glioma, and other cancers that express the Epidermal Growth Factor Receptor (EGFR). It is prescribed as part of a targeted anticancer therapy regimen.

Q: When should Biomab EGFR be used during cancer treatment?

A: The timing and frequency of Biomab EGFR administration depend on your oncologists recommendation. Typically, it is given once weekly or as determined by the treating physician based on your specific cancer type and condition.

Q: Where should Biomab EGFR - Nimotuzumab Injection be stored?

A: Store Biomab EGFR in a refrigerator at 2C to 8C. Do not freeze the vials, and ensure they are protected from exposure to light to maintain the medications effectiveness.

Q: What precautions should be taken when preparing Biomab EGFR for infusion?

A: Biomab EGFR must be diluted according to the manufacturers instructions and should not be mixed with other medicinal products unless specified in official guidelines. All preparation and administration steps should be performed by qualified healthcare personnel.

Q: Who should use Biomab EGFR Injection, and is pediatric usage possible?

A: Biomab EGFR is primarily intended for adult cancer patients. Pediatric use is possible, but only upon the specific recommendation and close supervision of a qualified oncologist.

Q: What are the potential benefits of Biomab EGFR in cancer therapy?

A: Biomab EGFR provides targeted action against EGFR-positive tumors, offering a high degree of specificity, which can help minimize off-target side effects such as skin and allergic reactions while effectively slowing tumor growth.

Get Latest Price